Uniongene's Novel Recombinant Biologics Production Base Inaugurated in TEDA

On November 8, the novel recombinant biologics production base of Uniongene Bioengineering (Tianjin) Co., Ltd. was inaugurated and put into operation in TEDA. With a total investment of 700 million yuan, the project will be constructed in two phases. The first phase, with an investment of 360 million yuan, focuses on a production line for long-acting growth hormone drugs. Upon full operation, the project is expected to achieve an annual output value of 5 billion yuan, significantly enhancing the international competitiveness of China's independent drug research and development capabilities.

Established in TEDA in 2023, Uniongene Bioengineering (Tianjin) Co., Ltd. is a comprehensive enterprise dedicated to the R&D and production of innovative biomacromolecule drugs. Equipped with advanced production and testing facilities for genetic engineering drugs, the company has assembled a top-tier R&D technical team. All products under development are independently researched and developed as Class I novel biologics.